|
|
|
| |
|
|
| |
The latest drug discovery news from News Medical |
|
|
|
 | | |
 Accelerate Your 3D Biology and Phenotypic Screening
Advancing 3D biology or phenotypic screening but limited by speed or image depth? Yokogawa’s high content imaging approaches support organoid and spheroid analysis, live cell time lapse studies, and next generation toxicology workflows—delivering fast, high resolution, low phototoxicity data for more translatable insights.
| |
|
|
|  | | |
| |
|
 Event guide: 16th Clinical Biomarkers & CDx Summit Europe
This event guide explores Europe’s leading meeting for biomarker and companion diagnostics professionals driving precision medicine forward. It looks at regulatory alignment, clinical validation, and commercialization strategies, with insights into how biomarkers are shaping smarter trials and targeted therapies.
|
|
| |  | | | | |  MIT Launches $3M AI and Synthetic Biology Project to Fight AMR MIT's new initiative combines synthetic biology and AI to develop programmable antibacterials, targeting antimicrobial resistance with precision and innovation. | | | | | | |  Bacteria-Powered Drug Discovery: A Greener Path to Curing "Undruggable" Cancers Researchers at the University of Bath have developed a new technology that uses bacteria to build, chemically stabilize, and test millions of potential drug molecules inside living cells, making it much quicker and easier to discover new treatments for difficult-to-treat cancers. | | | | | | |  SolasCure completes Phase II clinical trial, demonstrating accelerated healing with Aurase Wound Gel SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced the successful completion of its second Phase II clinical trial, CLEANVLU2. | | | | | | |  Phase 2 clinical trial tests LMP744 for the treatment of first-time recurrent glioblastoma Gibson Oncology, a clinical-stage private pharmaceutical company headquartered in Miami, announced it has entered Phase 2 clinical trials with LMP744 for the treatment of first-time recurrent glioblastoma patients. | |
|
|
| | | | How would you rate today's newsletter?
| |
|
|
| | | |
 |
Stay updated with the latest in health and medical news! Follow News‑Medical.net on Google News for real‑time updates. Click here to follow us now. |
| |
|
|
|
|
|
|
|
